Document:

2006 Equity Incentive Plan

 Exhibit 10.7 
 ALIEN TECHNOLOGY CORPORATION 
 2006 EQUITY INCENTIVE PLAN 
 1. Purposes of the Plan. The purposes of this Plan are: 
  

	 	•	 	to attract and retain the best available personnel for positions of substantial responsibility, 

  

	 	•	 	to provide additional incentive to Employees, Directors and Consultants, and 

  

	 	•	 	to promote the success of the Company’s business. 

 The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares. 
 2. Definitions. As used herein, the following definitions will apply: 
 (a) “Administrator” means the Board or any of its Committees as will be administering the Plan, in accordance with
Section 4 of the Plan. 
 (b) “Applicable Laws” means the requirements relating to the administration of
equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or
jurisdiction where Awards are, or will be, granted under the Plan. 
 (c) “Award” means, individually or
collectively, a grant under the Plan of Options, SARs, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares. 
 (d) “Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and
conditions of the Plan. 
 (e) “Board” means the Board of Directors of the Company. 
 (f) “Change in Control” means the occurrence of any of the following events: 
 (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner”
(as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or

 (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;

 (iii) A change in the composition of the Board occurring within a two-year period, as a
result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” means directors who either (A) are Directors as of the effective date of the Plan, or (B) are elected, or nominated for
election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or
threatened proxy contest relating to the election of directors to the Company); or 
 (iv) The consummation of a merger or
consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding
immediately after such merger or consolidation. 
 (g) “Code” means the Internal Revenue Code of 1986, as
amended. Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code. 
 (h) “Committee” means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board in accordance with Section 4 hereof. 
 (i) “Common Stock” means the common stock of the Company. 
 (j) “Company” means Alien Technology Corporation, a Delaware corporation, or any successor thereto. 
 (k) “Consultant” means any person, including an advisor, engaged by the Company or a Parent or Subsidiary to render
services to such entity. 
 (l) “Director” means a member of the Board. 
 (m) “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code, provided that in
the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from
time to time. 
 (n) “Employee” means any person, including Officers and Directors, employed by the Company
or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director’s fee by the Company will be sufficient to constitute “employment” by the Company. 
 (o) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 (p) “Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled in exchange
for Awards of the same type (which may have lower 

  

 -2- 

 
exercise prices and different terms), Awards of a different type, and/or cash, and/or (ii) the exercise price of an outstanding Award is reduced. The
Administrator will determine the terms and conditions of any Exchange Program in its sole discretion. 
 (q) “Fair
Market Value” means, as of any date, the value of Common Stock determined as follows: 
 (i) If the Common Stock is
listed on any established stock exchange or a national market system, including without limitation the Nasdaq National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its Fair Market Value will be the closing sales price for such
stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 
 (ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 
 (iii) For purposes of any Awards granted on the Registration Date, the Fair Market Value will be the initial price to the public as set
forth in the final prospectus included within the registration statement in Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Company’s Common Stock; or 
 (iv) In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the
Administrator. 
 (r) “Fiscal Year” means the fiscal year of the Company. 
 (s) “Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the meaning of
Section 422 of the Code and the regulations promulgated thereunder. 
 (t) “Inside Director” means a
Director who is an Employee. 
 (u) “Nonstatutory Stock Option” means an Option that by its terms does not
qualify or is not intended to qualify as an Incentive Stock Option. 
 (v) “Officer” means a person who is an
officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. 
 (w) “Option” means a stock option granted pursuant to the Plan. 
 (x)
“Optioned Stock” means the Common Stock subject to an Award. 
 (y) “Outside Director” means
a Director who is not an Employee. 
  

 -3- 

 (z) “Parent” means a “parent corporation,” whether now or
hereafter existing, as defined in Section 424(e) of the Code. 
 (aa) “Participant” means the holder of
an outstanding Award. 
 (bb) “Performance Share” means an Award denominated in Shares which may be earned in
whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine pursuant to Section 10. 
 (cc) “Performance Unit” means an Award which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine and which may be
settled for cash, Shares or other securities or a combination of the foregoing pursuant to Section 10. 
 (dd)
“Period of Restriction” means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based
on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator. 
 (ee) “Plan” means this 2006 Equity Incentive Plan. 
 (ff)
“Registration Date” means the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(g) of the Exchange Act, with respect to any class of the Company’s
securities. 
 (gg) “Restricted Stock” means Shares issued pursuant to a Restricted Stock award under
Section 7 of the Plan, or issued pursuant to the early exercise of an Option. 
 (hh) “Restricted Stock
Unit” means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 8. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. 

(ii) “Rule 16b-3” means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is
being exercised with respect to the Plan. 
 (jj) “Section 16(b)” means Section 16(b) of the
Exchange Act. 
 (kk) “Service Provider” means an Employee, Director or Consultant. 
 (ll) “Share” means a share of the Common Stock, as adjusted in accordance with Section 14 of the Plan. 

(mm) “Stock Appreciation Right” or “SAR” means an Award, granted alone or in connection with an
Option, that pursuant to Section 9 is designated as a SAR. 
 (nn) “Subsidiary” means a “subsidiary
corporation”, whether now or hereafter existing, as defined in Section 424(f) of the Code. 
  

 -4- 

 3. Stock Subject to the Plan. 
 (a) Stock Subject to the Plan. Subject to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares
that may be optioned and sold under the Plan is 7,500,000 Shares plus an annual increase to be added on the first day of the Company’s fiscal year beginning with the Company’s 2007 fiscal year, equal to the least of
(A) 2,500,000 Shares, (B) 4% of the outstanding Shares on such date or (C) an amount determined by the Board. The Shares may be authorized, but unissued, or reacquired Common Stock. 
 (b) Lapsed Awards. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to
an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units, is forfeited to or repurchased by the Company, the unpurchased Shares (or for Awards other than Options and SARs, the
forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). With respect to SARs, only Shares actually issued pursuant to an SAR will cease to be
available under the Plan; all remaining Shares under SARs will remain available for future grant or sale under the Plan (unless the Plan has terminated). However, Shares that have actually been issued under the Plan under any Award will not be
returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares of Restricted Stock, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company,
such Shares will become available for future grant under the Plan. Shares used to pay the tax and exercise price of an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash
rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment provided in Section 14, the maximum number of Shares that may
be issued upon the exercise of Incentive Stock Options shall equal the aggregate Share number stated in Section 3(a), plus, to the extent allowable under Section 422 of the Code, any Shares that become available for issuance under the Plan
under this Section 3(b). 
 (c) Share Reserve. The Company, during the term of this Plan, will at all times
reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan. 
 4. Administration of
the Plan. 
 (a) Procedure. 
 (i) Multiple Administrative Bodies. Different Committees with respect to different groups of Service Providers may administer the
Plan. 
 (ii) Section 162(m). To the extent that the Administrator determines it to be desirable to qualify
Options granted hereunder as “performance-based compensation” within the meaning of Section 162(m) of the Code, the Plan will be administered by a Committee of two or more “outside directors” within the meaning of
Section 162(m) of the Code. 
  

 -5- 

 (iii) Rule 16b-3. To the extent desirable to qualify transactions hereunder as
exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3. 
 (iv) Other Administration. Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which committee will be constituted to satisfy Applicable Laws. 

(b) Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific
duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: 
 (i) to
determine the Fair Market Value; 
 (ii) to select the Service Providers to whom Awards may be granted hereunder; 

(iii) to determine the number of Shares to be covered by each Award granted hereunder; 
 (iv) to approve forms of agreement for use under the Plan; 
 (v) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or
limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine; 
 (vi) to institute an Exchange Program; 
 (vii) to construe and interpret the terms of the
Plan and Awards granted pursuant to the Plan; 
 (viii) to prescribe, amend and rescind rules and regulations relating to the
Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws; 
 (ix) to modify or amend each Award (subject to Section 19(c) of the Plan), including the discretionary authority to extend the post-termination exercisability period of Awards longer than is otherwise provided for in the Plan;

 (x) to allow Participants to satisfy withholding tax obligations in such manner as prescribed in Section 15;

 (xi) to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award
previously granted by the Administrator; 
  

 -6- 

 (xii) to allow a Participant to defer the receipt of the payment of cash or the delivery
of Shares that would otherwise be due to such Participant under an Award 
 (xiii) to make all other determinations deemed
necessary or advisable for administering the Plan. 
 (c) Effect of Administrator’s Decision. The
Administrator’s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards. 
 5. Eligibility. Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares may be granted to Service Providers. Incentive Stock Options may be granted
only to Employees. 
 6. Stock Options. 
 (a) Limitations. 
 (i) Each Option will be designated in the Award Agreement as either
an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by
the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds $100,000, such Options will be treated as Nonstatutory Stock Options. For purposes of this Section 6(a), Incentive Stock Options will
be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. 
 (ii) The following limitations will apply to grants of Options: 
 (1) No Service Provider will be granted, in any Fiscal Year, Options to purchase more than 1,500,000 Shares. 
 (2) In connection with his or her initial service, a Service Provider may be granted Options to purchase up to an additional 3,000,000
Shares, which will not count against the limit set forth in Section 6(a)(2)(ii)(1) above. 
 (3) The foregoing
limitations will be adjusted proportionately in connection with any change in the Company’s capitalization as described in Section 14. 
 (4) If an Option is cancelled in the same Fiscal Year in which it was granted (other than in connection with a transaction described in Section 14), the cancelled Option will be counted against the limits set
forth in subsections (1) and (2) above. For this purpose, if the exercise price of an Option is reduced, the transaction will be treated as a cancellation of the Option and the grant of a new Option. 
 (b) Term of Option. The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, the
term will be ten (10) years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of an 

  

 -7- 

 
Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent
(10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in
the Award Agreement. 
 (c) Option Exercise Price and Consideration. 
 (i) Exercise Price. The per share exercise price for the Shares to be issued pursuant to exercise of an Option will be determined
by the Administrator, subject to the following: 
 (1) In the case of an Incentive Stock Option 
 a) granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent
(10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than 110% of the Fair Market Value per Share on the date of grant. 
 b) granted to any Employee other than an Employee described in paragraph (A) immediately above, the per Share exercise price will be
no less than 100% of the Fair Market Value per Share on the date of grant. 
 c) Notwithstanding the foregoing, Incentive
Stock Options may be granted with a per Share exercise price of less than 100% of the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code.

 (2) In the case of a Nonstatutory Stock Option, the per Share exercise price will be determined by the Administrator. In
the case of a Nonstatutory Stock Option intended to qualify as “performance-based compensation” within the meaning of Section 162(m) of the Code, the per Share exercise price will be no less than 100% of the Fair Market Value per
Share on the date of grant. 
 (ii) Waiting Period and Exercise Dates. At the time an Option is granted, the
Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised. 
 (iii) Form of Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option,
including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. Such consideration may consist entirely of: (1) cash; (2) check;
(3) promissory note; (4) other Shares, provided Shares acquired directly or indirectly from the Company, (A) have been owned by the Participant and not subject to substantial risk of forfeiture for more than six months on the date of
surrender, and (B) have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Option will be exercised; (5) consideration received by the Company under a cashless exercise program
implemented by the Company in connection with the Plan; (6) a reduction in the amount of any Company liability to the Participant, including any liability attributable to the Participant’s 

  

 -8- 

 
participation in any Company-sponsored deferred compensation program or arrangement; (7) any combination of the foregoing methods of payment; or
(8) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws. 
 (d) Exercise of Option. 
 (i) Procedure for Exercise; Rights as a Stockholder. Any Option granted
hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share.

 An Option will be deemed exercised when the Company receives: (i) notice of exercise (in such form as the Administrator specify from
time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with an applicable withholding taxes). Full payment may consist of any consideration and
method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the
Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a
stockholder will exist with respect to the Optioned Stock, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or
other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14 of the Plan. 
 Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. 
 (ii) Termination of Relationship as a Service Provider. If a Participant ceases to be a Service Provider, other than upon the
Participant’s death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than
the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3) months following the Participant’s termination.
Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the
Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan. 
 (iii) Disability of Participant. If a Participant ceases to be a Service Provider as a result of the Participant’s Disability,
the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as
set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following the Participant’s termination. 

  

 -9- 

 
Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares
covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will
revert to the Plan. 
 (iv) Death of Participant. If a Participant dies while a Service Provider, the Option may be
exercised following the Participant’s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of
the term of such Option as set forth in the Award Agreement), by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to Participant’s death in a form acceptable to the Administrator. If no such
beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred pursuant to the Participant’s will or in
accordance with the laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant’s death. Unless otherwise provided by the
Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time
specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan. 
 7. Restricted Stock.

 (a) Grant of Restricted Stock. Subject to the terms and provisions of the Plan, the Administrator, at any time and
from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. 
 (b) Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and
conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed. 

(c) Transferability. Except as provided in this Section 7, Shares of Restricted Stock may not be sold, transferred,
pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. 
 (d)
Other Restrictions. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate. 
 (e) Removal of Restrictions. Except as otherwise provided in this Section 7, Shares of Restricted Stock covered by each
Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine. The Administrator, in its discretion, may
accelerate the time at which any restrictions will lapse or be removed. 
  

 -10- 

 (f) Voting Rights. During the Period of Restriction, Service Providers holding
Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. 
 (g) Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect
to such Shares unless otherwise provided in the Award Agreement. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock
with respect to which they were paid. 
 (h) Return of Restricted Stock to Company. On the date set forth in the Award
Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. 
 8. Restricted Stock Units. 
 (a) Grant. Restricted Stock Units may be granted
at any time and from time to time as determined by the Administrator. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it shall advise the Participant in an Award Agreement of the terms, conditions, and
restrictions related to the grant, including the number of Restricted Stock Units and the form of payout, which, subject to Section 8(d), may be left to the discretion of the Administrator. 
 (b) Vesting Criteria and Other Terms. The Administrator shall set vesting criteria in its discretion, which, depending on the
extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may set vesting criteria based upon the achievement of Company-wide, business unit, or individual
goals (including, but not limited to, continued employment), or any other basis determined by the Administrator in its discretion. 
 (c) Earning Restricted Stock Units. Upon meeting the applicable vesting criteria, the Participant shall be entitled to receive a payout as specified in the Restricted Stock Unit Award Agreement. Notwithstanding the foregoing, at any
time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout. 
 (d) Form and Timing of Payment. Payment of earned Restricted Stock Units shall be made as soon as practicable after the date(s) set
forth in the Restricted Stock Unit Award Agreement. The Administrator, in its sole discretion, may pay earned Restricted Stock Units in cash, Shares, or a combination thereof. Shares represented by Restricted Stock Units that are fully paid in cash
again shall be available for grant under the Plan. 
 (e) Cancellation. On the date set forth in the Restricted Stock
Unit Award Agreement, all unearned Restricted Stock Units shall be forfeited to the Company. 
  

 -11- 

 9. Stock Appreciation Rights. 
 (a) Grant of SARs. Subject to the terms and conditions of the Plan, a SAR may be granted to Service Providers at any time and from
time to time as will be determined by the Administrator, in its sole discretion. 
 (b) Number of Shares. The
Administrator will have complete discretion to determine the number of SARs granted to any Service Provider. 
 (c)
Exercise Price and Other Terms. The Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of SARs granted under the Plan. 
 (d) SAR Agreement. Each SAR grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the
SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine. 
 (e) Expiration of SARs. An SAR granted under the Plan will expire upon the date determined by the Administrator, in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of
Section 6(d) also will apply to SARs. 
 (f) Payment of SAR Amount. Upon exercise of an SAR, a Participant will be
entitled to receive payment from the Company in an amount determined by multiplying: 
 (i) The difference between the Fair
Market Value of a Share on the date of exercise over the exercise price; times 
 (ii) The number of Shares with respect to
which the SAR is exercised. 
 At the discretion of the Administrator, the payment upon SAR exercise may be in cash, in Shares of equivalent
value, or in some combination thereof. 
 10. Performance Units and Performance Shares. 
 (a) Grant of Performance Units/Shares. Performance Units and Performance Shares may be granted to Service Providers at any time and
from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant. 
 (b) Value of Performance Units/Shares. Each Performance Unit will have an initial value that is established by the Administrator on
or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant. 
 (c) Performance Objectives and Other Terms. The Administrator will set performance objectives or other vesting provisions (including, without limitation, continued status as a Service Provider) in its
discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service 

  

 -12- 

 
Providers. The time period during which the performance objectives or other vesting provisions must be met will be called the “Performance Period.”
Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set
performance objectives based upon the achievement of Company-wide, divisional, or individual goals, applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion. 
 (d) Earning of Performance Units/Shares. After the applicable Performance Period has ended, the holder of Performance Units/Shares
will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting
provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share. 
 (e) Form and Timing of Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon as
practicable after the expiration of the applicable Performance Period. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of
the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof. 
 (f)
Cancellation of Performance Units/Shares. On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan. 
 11. Formula Option Grants to Outside Directors. 
 (a) General. Outside Directors will be entitled to receive all types of Awards under this Plan, including discretionary Awards not covered under this Section 11. All grants of Options to Outside Directors
pursuant to this Section will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions: 
 (b) Type of Option. All Options granted pursuant to this Section will be Nonstatutory Stock Options and, except as otherwise
provided herein, will be subject to the other terms and conditions of the Plan. 
 (c) No Discretion. No person will
have any discretion to select which Outside Directors will be granted Options under this Section or to determine the number of Shares to be covered by such Options (except as provided in Sections 11(g) and 14). 
 (d) Initial Option. Each person who first becomes an Outside Director following the Registration Date will be automatically granted
an Option to purchase 15,000 Shares (the “Initial Option”) on or about the date on which such person first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a
vacancy; provided, however, that an Inside Director who ceases to be an Inside Director, but who remains a Director, will not receive a First Option. 
  

 -13- 

 (e) Annual Option. Each Outside Director will automatically be granted an Option
to purchase 12,000 Shares (an “Annual Option”) on each date of the annual meeting of the stockholders of the Company beginning in 2006, if as of such date, he or she will have served on the Board for at least the preceding six
(6) months. Each person who, as of the Registration Date, serves as an Outside Director and is not described under Section 11(e)(i) below will receive an Annual Option on the Registration Date and, thereafter, such Outside Director will be
eligible to receive an Annual Option in accordance with the terms of this Section 11(e). 
 (i) Notwithstanding the
provisions of Section 11(e), an Outside Director who has been granted an option under the Company’s 1997 Stock Plan prior to the Registration Date will not be eligible to receive an Annual Option until all options granted to such Outside
Director under the Company’s 1997 Stock Plan have fully vested. 
 (f) Terms. The terms of each Option granted
pursuant to this Section will be as follows: 
 (i) The term of the Option will be ten (10) years. 
 (ii) The exercise price per Share will be 100% of the Fair Market Value per Share on the date of grant of the Option. 
 (iii) Subject to Section 14, the Initial Option will vest over three (3) years with 1/36 of the Shares subject to such Option
vesting monthly, provided that the Participant continues to serve as a Director through each such date. 
 (iv) Subject to
Section 14, the Annual Option will vest over three (3) years with 1/36 of the Shares subject to such Option vesting monthly, provided that the Participant continues to serve as a Director through such date. 
 (g) Amendment. The Administrator in its discretion may change the number of Shares subject to the First Options and Subsequent
Options. 
 12. Leaves of Absence. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended
during any unpaid leave of absence. A Service Provider will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent,
or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed ninety (90) days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence
approved by the Company is not so guaranteed, then three (3) months following the 91st day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax
purposes as a Nonstatutory Stock Option. 
 13. Transferability of Awards. Unless determined otherwise by the Administrator, an Award
may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime 

  

 -14- 

 
of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions
as the Administrator deems appropriate. 
 14. Adjustments; Dissolution or Liquidation; Merger or Change in Control. 
 (a) Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or
other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate
structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, shall adjust the number and class of Shares
that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, the numerical Share limits in Sections 3 and 6 of the Plan and the number of Shares issuable pursuant to Options to be
granted under Section 11. 
 (b) Dissolution or Liquidation. In the event of the proposed dissolution or
liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior
to the consummation of such proposed action. 
 (c) Change in Control. In the event of a merger or Change in Control,
each outstanding Award will be treated as the Administrator determines, including, without limitation, that each Award be assumed or an equivalent option or right substituted by the successor corporation or a Parent or Subsidiary of the successor
corporation. The Administrator shall not be required to treat all Awards similarly in the transaction. 
 In the event that the successor
corporation does not assume or substitute for the Award, unless the Administrator provides otherwise, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including
Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Performance Shares and Performance Units, all Performance Goals or other
vesting criteria will be deemed achieved at target levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a Change in Control, the Administrator will notify
the Participant in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon
the expiration of such period. 
 For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in
Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) or, in the case of a Stock
Appreciation Right upon the exercise of which the Administrator determines to pay cash or a Performance Share or Performance Unit which the Administrator can determine to pay in cash, the fair market value of the consideration received in the merger
or Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of 

  

 -15- 

 
consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Change in Control
is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or
upon the payout of a Restricted Stock Unit, Performance Share or Performance Unit, for each Share subject to such Award (or in the case of Restricted Stock Units and Performance Units, the number of implied shares determined by dividing the value of
the Restricted Stock Units and Performance Units, as applicable, by the per share consideration received by holders of Common Stock in the Change in Control), to be solely common stock of the successor corporation or its Parent equal in fair market
value to the per share consideration received by holders of Common Stock in the Change in Control. 
 Notwithstanding anything in this
Section 14(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the
Participant’s consent; provided, however, a modification to such performance goals only to reflect the successor corporation’s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.

 (d) Termination Following Change of Control. With respect to Awards granted to an Outside Director that are assumed or substituted
for, if on the date of or following such assumption or substitution the Participant’s status as a Director or a director of the successor corporation, as applicable, is terminated other than upon a voluntary resignation by the Participant, then
the Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Optioned Stock, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on
Restricted Stock and Restricted Stock Units will lapse, and, with respect to Performance Shares and Performance Units, all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and conditions met.

 15. Tax Withholding. 
 (a) Withholding Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a
Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant’s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).

 (b) Withholding Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may
specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (a) paying cash, (b) electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market
Value equal to the minimum amount required to be withheld, or (c) delivering to the Company already-owned Shares having a Fair Market Value equal to the minimum amount required to be withheld. The amount of the withholding requirement will be
deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant
with respect 

  

 -16- 

 
to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be
determined as of the date that the taxes are required to be withheld. 
 16. No Effect on Employment or Service. Neither the Plan nor
any Award will confer upon a Participant any right with respect to continuing the Participant’s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant’s right or the Company’s
right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws. 
 17. Date of
Grant. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be
provided to each Participant within a reasonable time after the date of such grant. 
 18. Term of Plan. Subject to Section 22 of
the Plan, the Plan will become effective upon its adoption by the Board. It will continue in effect for a term of ten (10) years unless terminated earlier under Section 19 of the Plan. 
 19. Amendment and Termination of the Plan. 
 (a) Amendment and Termination. The Board may at any time amend, alter, suspend or terminate the Plan. 
 (b) Stockholder Approval. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws. 
 (c) Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the Plan will impair the rights of
any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator’s
ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination. 
 20. Conditions Upon Issuance of Shares. 
 (a) Legal Compliance. Shares will not be issued pursuant to
the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.

 (b) Investment Representations. As a condition to the exercise of an Award, the Company may require the person
exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the
Company, such a representation is required. 
  

 -17- 

 21. Inability to Obtain Authority. The inability of the Company to obtain authority from any
regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or
sell such Shares as to which such requisite authority will not have been obtained. 
 22. Stockholder Approval. The Plan will be
subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan is adopted. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws. 
  

 -18-Agreement between the registrant and Impinj, Inc.

 Exhibit 10.36 
 CONFIDENTIAL INFORMATION REQUESTED BY ALIEN TECHNOLOGY CORP. 
 FIRST AMENDMENT TO AGREEMENT

 This FIRST AMENDMENT TO AGREEMENT (the “First Amendment”) is made and effective as of September 29, 2005, by and
between Alien Technology Corporation, a Delaware corporation (“Alien”) and Impinj, Inc., a Delaware corporation (“Impinj”) under the following circumstances: 
 A. On June 10, 2005, Alien and Impinj entered into an Agreement (“Agreement”) for the supply of Gen 2 Specification compliant RFID tag
silicon integrated circuits (“Monza”); and 
 B. Alien and Impinj desire to modify the terms of the Agreement on such terms and
conditions as are set forth in this First Amendment. 
 NOW THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which hereby are expressly acknowledged, the Parties agree as follows: 
 1. Any words with an
initial capitalized letter in this Amendment not defined in this First Amendment shall have the meaning given to such words in the Agreement. Terms defined in this First Amendment that are not defined in the Agreement shall have the meaning given to
such term herein. 
 2. Without waiving rights or obligations under the Agreement, the parties acknowledge that the Product Acceptance Date
is September 29, 2005. Alien shall pay Impinj the Pre-Paid Amount not later than seven (7) days following the effective date of this First Amendment. 
 3. With respect to the Pre-Paid Amount, Impinj’s estimated NRE fees for the development of Monza-FSA, in lieu of the first two sentences of Section 6(e) of the Agreement, will be [***] split into three
categories: 
 (a) Wafer and mask charges ([***]) 
 As a consequence of (a) above, Impinj will incur expenses of approximately [***] for mask charges and to procure the preliminary 6 wafers from 2 separate engineering lots for Impinj evaluation of Monza-FSA.

 (b) Labor charges ([***]) 
 Impinj will use commercially reasonable efforts to keep Labor charges (b, above) less than [***], provided however that the Labor charges to Alien shall in no event exceed [***]. These charges will cover labor hours related to design,
layout, test engineering and evaluation of Monza-FSA. Costs above [***] for (b) above need to be mutually agreed to before being incurred by Impinj. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Delivery of six Monza-FSA wafers to Alien ([***]) 
 Per section 3(c) above, Impinj will make available 6 additional wafers of Monza-FSA to Alien for the purposes of determining suitability for the FSA
process. 
 All other Monza-FSA wafers purchased by Alien will not be considered as a portion of the NRE fees (defined in sections (5.(a).iii.1) and
(6.e) of the Agreement. 
 Impinj will meet the following schedule: 
  

					
	  	  	 Milestone
	  	 Date

	 (i)
	  	 Start Monza 1A layout for FSA
	  	 [***] (target date).

	 (ii)
	  	 Tapeout of Monza-FSA
	  	 [***] (target date).

	 (iii)
	  	 Engineering silicon samples
	  	 [***] (target date).

	 (iv)
	  	 Production
	  	 UponAlien acceptance & release, but not later than [***].

 All of the provisions of the Agreement not specifically amended as set forth in this First
Amendment remain in full force and effect. Except as expressly set forth herein, nothing in this First Amendment shall be construed to constitute a waiver by Impinj or Alien of any provision of the Agreement. This First Amendment along with the
Agreement (including the exhibits thereto) contain the entire agreement between the parties with respect to the subject matter of this First Amendment and the Agreement and supersede all previous communications, representations, understandings and
agreements, either oral or written, between the parties with respect to said subject matter. This First Amendment may be executed in counterparts, each of which when so executed will be deemed an original and such counterparts together will
constitute one and the same agreement. 
  

									
	Alien Technology Corporation	 		 	Impinj, Inc.
					
	 By: 
	 	 /s/ John Payne
	 		 	 By: 
	 	 /s/ William T. Colleran

			
	 Print Name:  John Payne
	 		 	 Print Name:  William T. Colleran

			
	 Title:  Chief Operating Officer
	 		 	 Title:  President

  

 2 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Agreement 
 This agreement (the “Agreement”) is entered into as of June 10, 2005 (the “Effective Date”) by and between Impinj, Inc., a Delaware corporation with its principal place of business
located at 501 N. 34th Street, Suite 100, Seattle, WA 98103 (“Impinj”), and Alien Technology Corporation, a Delaware corporation with its principal place of business located at 18220 Butterfield Blvd., Morgan Hill, CA 95037
(“Alien”) (each a “party” and collectively the “parties”). 
 Recitals 

Impinj desires to sell to Alien, and Alien desires to purchase from Impinj, Impinj’s initial implementation of EPCglobal’s Gen 2
Specification compliant RFID tag silicon integrated circuit (“Monza”) and/or certain future versions of Monza, as set forth below; 
 The parties desire that Alien place an immediate order of 24 risk wafers of Monza, Alien commit to a prepayment in the amount of [***], Alien commit to a minimum purchase amount of 50,000,000 units of Product, and that Impinj perform its
obligations and deliver the deliverables required of it hereunder so that Alien may assemble RFID straps, inlay and/or label products using wafers supplied by Impinj hereunder, all as set forth below; 
 In consideration of the mutual promises contained herein, the parties agree as follows: 
 Agreement 
  

	1.	Definitions. The following terms shall have the following meanings: 

 “Confidential Information” means any information disclosed by one party to the other in connection with the performance of this Agreement, including Intellectual Property and other information that
relates to the disclosing party’s products, designs, business plans, business opportunities, finances, research, development, know-how, personnel, or third-party confidential information disclosed to the receiving party by the disclosing party
in any form whatsoever (including, but limited to, disclosure made in writing, orally or in the form of samples, models, computer programs or otherwise), and the terms and conditions of this Agreement, provided that such information is at the time
of disclosure either designated as “confidential”, “proprietary,” or similar legend or reasonably should be known to the receiving party to be confidential. Confidential Information does and will not include material that:
(i) is now or subsequently becomes generally available to the public or is disclosed to third parties without restriction on its use or disclosure; (ii) the receiving party had rightfully in its possession prior to disclosure by the
disclosing party; (iii) is developed independently by or for the receiving party without the use of any Confidential Information of the disclosing party; (iv) the receiving party rightfully obtains without restriction from a third party
who has the right to transfer or disclose it; or (v) is disclosed with the prior written approval of the disclosing party. 
  

 3 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Assembled Parts” means a Product included as a component of an Alien strap, inlay
or finished label that is intended for shipment to Alien’s customer. 
 “EPCglobal” means EPCglobal Inc., and its
successors and assigns. 
 “Epidemic Failure” means a series of failures (i) indicating a common or systemic Product
failure related to the same or similar root cause, (ii) equal to or in excess of [***] of the total number of Assembled Parts during any rolling [***] month period; and (iii) resulting in the failure of Products to meet the Limited
Product Warranty, (iv) during the Limited Warranty Period. 
 “FSA Intellectual Property” has the meaning set forth in
Section 2(c). 
 “Gen2 Specification” means any Class 1, Generation 2 specification that is ratified by
EPCglobal’s Board of Governors. 
 “Intellectual Property” means all circuit designs, hardware description language
coding, software (including firmware), simulation models, schematics, layout topologies, cells, libraries, data, formulas, designs, software, other original works of authorship, applications, processes, products, know-how, techniques, programs,
improvements, test protocols, test structures, characterization and test results, methods and patterns, specifications and other technical information, whether or not patentable or otherwise protectable. 
 “Intellectual Property Rights” means all copyright rights, patent rights (including reissues, divisions, renewals, extensions,
provisionals, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries), trademark rights, trade secret rights, moral rights, rights of publicity, authors’ rights,
semiconductor mask work rights, contract and licensing rights, goodwill and all other intellectual property rights as may exist now and/or hereafter come into existence and all applications therefor and registrations, renewals and extensions
thereof, regardless of whether such rights arise under the law of the United States or any other state, country, jurisdiction or international treaty. 
 “KGD” shall mean the known good die on a Product wafer. For Monza and Monza-2 wafers, the number of known good die will be determined as measured by Impinj during Testing of the Product in wafer form.
For Monza-FSA, the number of known good die will be determined by Impinj via the Sample Testing Procedure. 
 “Limited Product
Warranty” shall have the meaning set forth in Section 9(a)(i). 
 “Limited Warranty Period” shall mean
one (1) year from the date that Products are received by Alien. 
 “Minimum Purchase Amount” shall have the meaning set
forth in Section 4(a). 
 “Monza” shall have the meaning set forth in the Recitals. 
  

 4 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Monza Specifications” shall have the meaning set forth in
Section 2(a)(i). 
 “Monza-2” shall have the meaning set forth in Section 2(b). 
 “Monza-2 Specifications” shall have the meaning set forth in Section 2(b). 
 “Monza-FSA” shall have the meaning set forth in Section 2(c). 
 “Monza-FSA Specifications” shall have the meaning set forth in Section 2(c). 
 “NRE” means non-recurring engineering. 
 “Order” shall have the meaning set forth in Section 8(a)(i). 
 “Pre-Paid Amount” shall have the meaning set forth in Section 5(a)(i). 
 “Product”
means Monza, Monza-2, and/or Monza-FSA, as applicable. 
 “Product Acceptance” shall have the meaning set forth in
Section 2(a). 
 “Product Acceptance Date” shall have the meaning set forth in Section 2(a).

 “Specifications” means either the Monza Specifications, Monza-2 Specifications or Monza-FSA Specifications. 

“Risk Wafers” shall have the meaning set forth in Section 3(a). 
 “Sample Testing Procedure” shall mean a process by which Impinj tests up to 200 die on a Monza-FSA wafer and extrapolates to determine
the number of good die on the entire wafer. A detailed definition of this process will be determined mutually at a later date. 
 “Testing” means those test procedures for Products as set forth in Exhibit B. 
 “Walmart” means
Wal-Mart Stores, Inc. 
  

	2.	Evaluation, Development and Product Specifications. 

 (a) Monza. 
 (i) Specifications. The Monza Specifications, including performance specifications,
current as of the Effective Date are set forth in Impinj’s documentation provided to Alien on or about May 18, 2005 (“Monza Specifications”), and attached hereto as Exhibit A. Monza shall perform in accordance with the
performance specifications included as part of the Monza Specifications. Impinj shall update the Monza Specifications from time to time as conditions warrant and to conform with the updates to the Gen2 Specification with the consent of 

  

 5 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Alien, which consent shall not be unreasonably withheld. When used in this Agreement, Monza Specifications refers to the most recent version agreed to by the
parties. 
 (ii) Product Acceptance. Impinj shall submit Monza to certify its compliance with the Gen2 Specification
according to procedures established by EPCglobal and, at its sole cost and expense, Impinj shall revise and resubmit Monza until such time as EPCglobal or one of its designated third party compliance laboratories certifies Monza as compliant with
the Gen2 Specification; provided however, that if after three (3) such submissions, Monza is not certified, the parties will discuss in good faith next steps to obtain certification for Monza, if obtainable, and Impinj shall not have further
obligation to submit Monza to EPCglobal. Any version of Monza that: (1) is certified by EPCglobal or one of its designated third party compliance laboratories as compliant with a Gen2 Specification; (2) implements a version of the Gen2
Specification that Walmart indicates it will accept; and (3) materially complies with the Monza Specifications, shall be deemed accepted hereunder (the “Product Acceptance”). The latter of the dates that: (1) a version of Monza
is certified as compliant with a Gen2 Specification in accordance with above; (2) Walmart first publicizes or otherwise indicates its intent to accept products compliant with such version of the Gen2 Specification; and (3) Testing for
Monza is completed, and Monza materially complies with the Monza Specifications, shall be the “Product Acceptance Date.” If, for any reason, Walmart publicizes or otherwise indicates its intent to no longer accept the version of the Gen2
Specification with which the Monza Specification is compliant, then (i) Impinj shall immediately notify Alien, (ii) Alien shall have the right to cancel any outstanding Orders in accordance with this Agreement, and thereafter
(iii) Alien shall have the right to terminate this Agreement. 
 (iii) Samples of Monza-Based Straps or Inlays.
Within eight (8) weeks of delivery of the first Risk Wafer (as described in Section 3(b)), Alien shall produce and deliver to Impinj at least one thousand (1,000) known good straps or inlays incorporating Monza die from such
Risk Wafer. Each party shall evaluate the performance of such straps or inlays within two (2) weeks of delivery to Impinj. The parties shall share the results of such performance evaluation. Such results shall be deemed Confidential Information
of both parties. Each party agrees not to distribute to any third party or otherwise allow any third party to sample any Alien-assembled strap or inlay incorporating any Monza die arising from the first Risk Wafer (as described in
Section 3(b)) without the prior written consent of the other party. 
 (b) Monza-2. Impinj may develop a cost-reduced
version of Monza (“Monza-2”) provided that Impinj shall have no obligation to develop, release or sell Monza-2. If Impinj decides to develop, release or sell Monza-2, the specifications for Monza-2 shall be as set forth by Impinj
(“Monza-2 Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience gained with Monza wafers. If it is evident that typical performance of
Monza is better than is reflected in the Specification, the acceptance specification for Monza-2 will be shifted toward more sensitivity, by mutual agreement of the parties. Provided that Alien is not in breach of this Agreement, Impinj will provide
Alien with early access and beta versions of Monza-2 and metal variants of Monza-2 no later than it provides access to other Impinj customers. 
  

 6 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Monza-FSA. Following receipt of the applicable NRE fees set forth herein, Impinj agrees to
use commercially reasonable efforts to develop a customized Monza product that is compatible with Alien’s patented “Fluidic Self Assembly” process (“Monza-FSA”); provided that Alien provides such information and
assistance as is reasonably requested by Impinj. Alien acknowledges and agrees that such development efforts may be unsuccessful and Impinj shall have no obligation to release or sell Monza-FSA. The specifications of the Monza-FSA (if and when
available) shall be as mutually agreed to by the parties in writing (“Monza-FSA Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience
gained with Monza wafers. If it is evident that typical performance of Monza is higher than is reflected in the Specification, the acceptance specification for Monza-FSA will be shifted toward more sensitivity, by mutual agreement of the parties.
Monza-FSA Specifications may include a test structure that will allow Impinj to use its standard test procedures to determine wafer yields on a sampling basis (i.e., wafers to include test structures built into reticles for Impinj to test prior to
sending to Alien). For those portions of the Monza-FSA that are Alien’s Intellectual Property as defined under Section 10(c) (“FSA Intellectual Property”), such FSA Intellectual Property shall be and remain Alien
Confidential Information. Impinj shall have no right to sell, license, transfer or otherwise distribute the FSA Intellectual Property. 
  

	3.	Risk Wafers. 

 (a) Definition. All orders by
Alien or deliveries by Impinj of Monza wafers shall be deemed “Risk Wafers” until Impinj provides written notice that it is releasing Monza into production. 
 (b) Initial Delivery of Risk Wafer. On or prior to June 30, 2005, Impinj shall deliver to Alien without charge or other expense one
(1) Risk Wafer along with one thousand (1,000) assembled Monza tags and one hundred (100) Monza die in waffle pack. 
 (c)
First Order and Delivery of Risk Wafers. On May 20, 2005, Alien issued a non-cancelable Order for [***] Risk Wafers (“Risk Wafer Order”). Impinj acknowledges receipt of the Risk Wafer Order. The schedule delivery date of
such Risk Wafers shall be twelve (12) weeks from May 20, 2005. For purposes of clarification, the single Risk Wafer delivered to Alien pursuant to Section 3(b) shall not be included within such [***] Risk Wafer Order. Except
for the restrictions of Section 2(a)(iii), nothing contained herein shall prevent Alien from selling or otherwise distributing straps, inlays, or labels built using the Risk Wafers purchased under this Section 3(c) to Alien’s
resellers and end customers. 
 (d) AS-IS Without Warranty. Alien acknowledges and agrees that all Risk Wafers are sold “AS
IS” without any warranty of any kind. 
  

	4.	Minimum Purchase Requirements. 

 (a) Total
Minimum Purchase Amount. During the term of this Agreement, subject to Impinj’s compliance with its material obligations and liabilities hereunder, Alien shall purchase a minimum of fifty million (50,000,000) units of Product
(“Minimum Purchase Amount”). Such minimum may 

  

 7 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
comprise any combination of units of Monza, Monza-2 and Monza-FSA, subject to Alien’s discretion and, in the case of Monza-2 and Monza-FSA, availability
from Impinj. Alien acknowledges that the Risk Wafer specified in Section 3(b) shall not be counted towards the Minimum Purchase Amount. Risk Wafers specified in Section 3(c) shall be counted towards the Minimum Purchase
Amount. In addition, the parties agree that the determination of the number of units of Product on a single wafer for purposes of accounting for the Minimum Purchase Amount shall be the number of KGD on that wafer. 
 (b) Timing of Minimum Purchase Amount. 
 (i) Subject to Section 4(d), Alien shall issue non-cancelable Orders for the Minimum Purchase Amount by July 1, 2006 and receive delivery of the same by October 1, 2006. 
 (ii) Subject to Section 4(d), Alien shall issue non-cancelable Orders and receive delivery for: (1) at least eight
million units (8 Mu) of Product by January 1, 2006; and (2) at least an additional twelve million units (12Mu) by April 1, 2006. Alien acknowledges and agrees that it shall place such Orders prior to the applicable Lead Times. 
 (c) Order Increments. Alien acknowledges and agrees that Impinj delivers Monza and Monza-2 in whole wafer increments. Alien acknowledges and
agrees that the yield of a particular wafer may vary and as such, the number of KGD on each wafer may vary. As such, in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order up to an additional fifty thousand (50,000)
units of Monza or Monza-2 Product. Alien acknowledges and agrees that Impinj delivers Monza-FSA in whole lot increments, consisting of twenty-five (25) wafers. Alien acknowledges and agrees that the yield of a particular lot may vary. As such,
in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order up to an additional twenty-five (25) wafer lot of Monza-FSA. 
 (d) Timing of Product Acceptance. In the event that the Product Acceptance Date does not occur by September 1, 2005, the delivery dates set forth in Section 4(b) shall be extended one day for
each day that the Product Acceptance Date is after September 1, 2005. For purpose of illustration, if the Product Acceptance Date occurs on September 21, 2005, each of the delivery dates set forth in Section 4(b) shall be
extended by twenty (20) days. 
  

	5.	Payments. 

 (a) Prepayments. 
 (i) Amount. Subject to Section 5(a)(ii), Alien shall pay Impinj a non-refundable five-hundred thousand dollars ($500,000)
(“Pre-Paid Amount”) as a prepayment for certain amounts due under this Agreement. 
 (ii) Timing.
Alien shall pay Impinj the Pre-Paid Amount the later of (1) seven (7) days following the Product Acceptance Date and (2) September 1, 2005; provided however that in the event the Product Acceptance date does not occur by
December 31, 2005 and Alien 

  

 8 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
terminates this Agreement pursuant to Section 13(b)(i), Alien shall have no obligation to pay the Pre-Paid Amount. 
 (iii) Allocation. 
 (1) NRE Fees for Development of Monza-FSA. The parties agree that the Pre-Paid Amount shall be used to fully satisfy the NRE fees due to Impinj for the development of Monza-FSA pursuant to
Section 6(e). 
 (2) Credit for Product Purchases In Excess of Forty Million Units. The parties agree that
the amount of the Pre-Paid Amount remaining after Alien has paid Impinj the applicable NRE fees due under Section 6(e) (i.e., $400,000 if the NRE fees are $100,000 or $300,000 if the NRE fees are $200,000) (the “Credit
Amount”) may be used as a credit against purchases of production orders of (i) Monza or Monza-2 versions of the Product in excess of the first forty million units (40 Mu) of production versions of Product ordered by Alien pursuant to
this Agreement, and (ii) Monza-FSA versions of the Product commencing on the initial production versions of Product ordered by Alien pursuant to this Agreement. The Credit Amount shall be credited against such purchases at a rate of $0.02 per
KGD. The Credit Amount must be used by Alien within six (6) months of the date Alien purchases its forty millionth unit of production Product. If Alien fails to fully use the Credit Amount by such date, Alien shall not be entitled to the
benefit of any remaining amount of the Credit Amount. 
 (b) Payment Terms. Alien shall pay Impinj all invoiced amounts net thirty
(30) days from the date of Alien’s receipt of each invoice. All payments due under this Agreement shall be made in US dollars by check or bank wire transfer to an account designated by Impinj. Without prejudice to any other remedy, in the
event any amount is not paid by Alien when due, following ten (10) business days written notice by Impinj to Alien during such time Alien having the right to cure, Impinj may assess, and Alien agrees to pay, a late charge of the lesser of one
and one quarter percent (1.25%) per month or the maximum percentage allowed by law for each month or portion thereof that the amount is past due. 
 (c) Taxes. Amounts payable to Impinj under this Agreement are payable in full to Impinj without deduction and are net of taxes (including any sales, use, excise, ad valorem, property, withholding, value added
tax, or other tax and any income tax withheld at source), tariff, duty or assessment levied or imposed by any government authority that may be applicable to the transactions contemplated by this Agreement based on delivery terms set forth in
Section 8(b), exclusive of taxes based on Impinj’s net income and any taxes (including those set forth above in this paragraph) prior to delivery to Alien. 
  

	6.	Fees and Prices. 

 (a) Risk Wafers. The price
of each Risk Wafer ordered by Alien pursuant to Section 3(c) shall be three thousand nine hundred sixty dollars ($3,960) per wafer. The total purchase price of the first order of Risk Wafers shall be ninety-five thousand forty dollars
($95,040). Additional risk wafers ordered (excluding Section 6(c)) will be priced in accordance with Section 6(b). 
  

 9 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (b) Prices of Product Purchased to Meet the Minimum Purchase Amount. 
 (i) Monza. For Monza Product that is purchased to meet the Minimum Purchase Amount, the unit price for each Monza KGD shall be
$0.076 subject to offset by the Credit Amount applicable to each unit. For purposes of clarification, Alien shall only be required to pay for each KGD on Monza wafers. As such, any non-KGD on any Monza wafer may not be used to satisfy any part of
the Minimum Purchase Amount. 
 (ii) Monza-2. For Monza-2 Product (if and when available) that is purchased to meet the
Minimum Purchase Amount, the unit price for each Monza-2 KGD shall be $0.076 multiplied by the ratio of the number of die on a Monza wafer over the number of die on a Monza-2 wafer (unless a lower unit price is mutually agreed by the parties in
writing) subject to offset by the Credit Amount applicable to each unit. For purposes of illustration, if the number of die on a Monza-2 wafer is 30% larger than the number of die on a Monza wafer, the unit price for each Monza-2 KGD shall be $0,076
* (1.0/1.3). For purposes of clarification, Alien shall only be required to pay for each KGD on Monza-2 wafers. As such, any non-KGD on any Monza-2 wafer may not be used to satisfy any part of the Minimum Purchase Amount. 
 (iii) Monza-FSA. For Monza-FSA Product (if and when available) that is purchased to meet the Minimum Purchase Amount, the unit
price for each Monza-FSA wafer shall be two thousand one hundred dollars ($2,100) (“MW Price”) subject to certain price adjustments as described below in this Section 6(b)(iii); provided, that Monza-FSA is available from Impinj in
production quantities prior to July 1, 2006. Additionally, in the event Monza-FSA wafer yields are less than the Minimum FSA Yield, then the MW Price shall be decreased to reflect the actual percentage yield below the Minimum FSA Yield. Commencing
with Impinj’s first shipment of production versions of Monza-FSA, the Minimum FSA Yield shall be eighty-five percent (85%), and shall increase by two percent (2%) for each Monza-FSA lot accepted by Alien thereafter up to a maximum of
ninety-five percent (95%). For Monza-FSA wafers whose yield is lower than the Minimum FSA Yield, Impinj will offer a price discount from the MW Price equal to the percentage difference between the actual yield of the wafer and the Minimum FSA Yield.
For purposes of clarification, in the event a wafer from the third lot of Monza-FSA shipped by Impinj has a yield of eighty-five percent (85%), then Alien will be entitled to a six percent (6%) discount from the MW Price for that wafer (6% discount
equals 91% Minimum FSA Yield less 85% actual wafer yield). Monza-FSA wafer yields will be set by the Sample Testing Procedure. 
 (c)
Prices of Product Purchased In Excess of the Minimum Purchase Amount. If Alien commits to purchase an annual volume of Products in excess of fifty million units (in addition to the Minimum Purchase Amount) under the terms and conditions of
this Agreement, Impinj agrees that the purchase prices for such Products shall be no higher than the prices set forth in Section 6(b). 
 (d) Most Favored Customer. During the term of this Agreement, Impinj agrees that if Impinj sells Products to a third party in similar volumes (within 20%) over similar time frames under pricing and other purchase terms and
conditions, taken as a whole, that are more favorable than the pricing and other purchase terms and conditions contained herein, this Agreement and any outstanding Orders shall be deemed automatically adjusted in pricing and other purchase terms and
conditions to reflect such more favorable pricing and other purchase terms and conditions. Impinj warrants that the terms and conditions reflected herein are equivalent or better than the most favorable pricing and other purchase terms and
conditions for Monza that it has provided any third party purchasing in similar volumes over similar time frames. 
 (e) NRE Fees for
Development of Monza-FSA. Alien shall pay Impinj one hundred thousand dollars as NRE fees in consideration of Impinj’s development efforts set forth in 

  

 10 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Section 2(c). The NRE fees may be increased to two hundred thousand dollars ($200,000) if mutually agreed to in writing by the parties. For
purposes of clarification, the NRE fee in this Section 6(e) is the same (and not in addition to) the NRE referenced elsewhere in this Agreement. 
  

	7.	Forecasts; Lead Times; Delivery Requirements. 

 (a)
Forecasts. Within the first ten (10) days of the beginning of each calendar month, Alien shall provide Impinj with a written twelve (12) month rolling forecast, updated monthly setting forth Alien’s estimated monthly
requirements for Products. The first [***] of such forecast shall be binding (subject to rescheduling, cancellation and other provisions hereof), and Alien shall issue non-cancelable Orders within the applicable Lead Times to cover such period. The
remaining [***] of such forecast shall be non-binding; provided, however, Alien may, in its discretion, issue non-cancelable Orders to cover such period. 
 (b) Lead Times. Alien acknowledges that the lead times for the Products in production quantities (“Lead Times”) are currently [***] for Monza and expected to be [***] for Monza-2 (if and when
available) and Monza-FSA (if and when available). Lead Times are associated with wafer processing alone and do not contemplate back end processing functions such as bumping, thinning, scribing, etc. Impinj shall provide Alien prompt written notice
if the Lead Times change. 
 (c) Delivery Requirements. 
 (i) Order Increments. Alien acknowledges and agrees that delivery of all Products shall be in accordance with Section 4(c).

 (ii) Yield of Product Wafers. Impinj acknowledges and agrees that it will not ship Monza or Monza-2 wafers to Alien
that have a yield less than [***], except as may be agreed upon by the parties in writing with price reductions as set forth below. Impinj acknowledges and agrees that it will not ship Monza-FSA wafers to Alien that have a yield less than [***],
except as may be agreed upon by the parties in writing with appropriate price reductions as set forth in Section 6(b)(iii), such yield to be determined in a manner to be mutually agreed to by the parties. For Monza-FSA, if Impinj fails to
deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer those wafers for sale to Alien with appropriate price reductions as set forth in
Section 6(b)(iii). For Monza and Monza-2, if Impinj fails to deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer a price discount equal to
the percentage difference between the actual yield of the wafer and [***]. For example, if Impinj sells a wafer to Alien with [***] yield, Alien will be entitled to a [***] discount on the KGD price which has been set in accordance with
Section 6(b). 
 (iii) Form of Monza and Monza-2 Wafers. The production versions of Monza and Monza-2 wafers
delivered to Alien shall not be bumped, thinned or otherwise post-processed. Such wafers shall be initialized (i.e., Impinj will program a valid electronic product 

  

 11 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
code into the appropriate 96-bit memory field of Monza or Monza-2 die) and provided with wafer maps that identify the KGD. 
 (iv) Form of Monza-FSA Wafers. The production versions of Monza-FSA wafers delivered to Alien shall pass standard process control
monitor (“PCM”) tests at Impinj’s foundry and such additional testing and initialization processes as agreed by the parties in the course of developing Monza-FSA. Impinj shall, at a minimum, sample test such wafers but Impinj shall
not be required to bump, thin or otherwise post-process such wafers. Any additional testing or initialization procedures shall be as mutually agreed in writing during the development of Monza-FSA. 
 (v) Performance of Monza and Monza-2 wafers. The wafers that Impinj provides to Alien will have no less sensitivity than those it
sells to others or uses for its own production. 
  

	8.	Order Process; Shipping and Title; Acceptance of Shipments. 

 (a) Order Process. 
 (i) All purchases and sales between Impinj and Alien hereunder shall be initiated by
Alien’s issuance of written purchase orders (“Orders”) to Impinj. All Orders shall include the following: (1) purchase order number; (2) Product number, description and price (by line item); (3) billing address;
(4) shipping address; (5) requested shipment date; (6) authorized signature; and (7) such other information as Impinj may reasonably request. 
 (ii) Impinj agrees to acknowledge Alien’s Orders in writing, or electronically where an electronic data interchange procedure has
been agreed to by the parties, within five (5) working days of receipt. If Impinj is unable to accept any purchase order, Impinj shall give Alien a written explanation. Impinj may not reject or amend any Order that conforms to the terms and
conditions of this Agreement, unless such Order is required to be reduced by allocation under Section 8(b)(iii). 
 (iii)
This Agreement shall govern all orders of Products by Alien. No terms on Orders, invoices or like documents by either party shall serve to alter or add to the terms of this Agreement unless agreed to and signed by both parties in writing.

 (iv) Without Impinj’s prior written consent and except as provided expressly herein, Alien shall have no right to make
any modifications or additions to any Order that has been accepted by Impinj. 
 (v) No later than sixty (60) days prior
to the shipping date, Alien may reschedule any Order for delivery up to thirty (30) days after the original shipping date without charge or penalty. Less than sixty (60) days prior to the shipping date, Alien may only reschedule an Order
with the consent of Impinj. 
  

 12 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (vi) Alien may cancel an Order at any time upon written notice to Impinj; provided,
however, that Alien pays to Impinj the amounts described in this section. Alien will be liable to pay to Impinj any penalties or cancellation fees charged to Impinj by Impinj’s suppliers as a direct consequence of Alien’s cancellation of
the Purchase Order, less any amounts charged for materials that are refundable (collectively, the “Cancellation Fee”). Notwithstanding the foregoing, unless expressly agreed to the contrary in writing by the parties at the time that the
Order is accepted, the Cancellation Fee may not exceed the total invoice value of the Order. Impinj will use its commercially reasonable efforts to minimize, and will perform any commercially reasonable acts necessary to mitigate, any applicable
Cancellation Fees. Upon receipt of notice of cancellation, Impinj will notify Alien within ten (10) business days of the precise amount of the Cancellation Fee, and Alien will have the right to either (1) withdraw its notice of
cancellation and require Impinj to continue to fulfill the Purchase Order; or (2) confirm the cancellation and pay the Cancellation Fee. Failure by Alien to notify Impinj of withdrawal of its notice of cancellation within five (5) business
days after receiving from Impinj the precise amount of the Cancellation Fee will be deemed confirmation of cancellation by Alien. Upon confirmation of any cancellation and receipt from Impinj of an invoice for a Cancellation Fee, Alien will pay the
full Cancellation Fee to Impinj in accordance with the terms of Section 5(b). Notwithstanding the foregoing, Alien may cancel any Order without the obligation to pay any cancellation fee if Impinj fails to deliver Products within thirty
(30) days after the scheduled shipping date. Except as set forth in Section 8(b)(ii), Orders cancelled prior to shipment will not apply towards the Minimum Purchase Amount. 
 (vii) In the event of a suspected Epidemic Failure, Alien shall promptly notify Impinj, and shall provide the following information, if
known and as may then exist: a description of the defect, and the suspected lot numbers, serial numbers or other identifiers, and delivery dates of the defective Products. Alien shall also make available to Impinj samples of the defective Products
for testing and analysis. Within five (5) business days of receipt of notice from Alien, Impinj shall provide its preliminary findings regarding the cause of the failures. Thereafter, Impinj shall promptly provide the results of its root cause
corrective analysis, its proposed plan for the identification of and the repair or replacement of the affected Products, and such other appropriate or desirable information as Alien may reasonably request. The parties shall also cooperate to
expeditiously devise and implement a corrective action program which identifies the defective units for repair or replacement, and which minimizes disruption to Alien’s customers. 
 (b) Shipping and Title. Delivery is FOB Impinj’s facilities (currently in Orange County, CA) (the “Delivery Point”). Title
to, and risk of loss of, the Products shall pass to Alien upon delivery by Impinj to Alien’s designated carrier at the Delivery Point. 
 (i) Impinj will handle and pack all Products so as to protect the Products from loss or damage in transit, in a manner consistent with standard commercial practice and approved by Alien. Subject to Sections 8(b)(ii)
and 8(b)(iii) below, Impinj will endeavor to ship the Impinj Products on or before the shipping date. 
 (ii) In the event of
any delays that cause the shipment to ship four (4) days or more after the scheduled shipping date, and without limiting Alien’s other rights and remedies 

  

 13 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
hereunder, Impinj shall immediately notify Alien of such delay and shall use its commercially reasonable efforts to remedy such delay immediately. In the
event of such delay, Alien may cancel the Order; provided however that the KGD for such shipment shall apply to the Minimum Purchase Amount (or in the event the KGD for such shipment is not known, then the amount attributable to the Minimum Purchase
Amount shall be an amount equal to the average KGD determined over the most recent wafer lot received by Alien). If not cancelled by Alien, Impinj shall use expedited means to ship the Products, at its own expense, to minimize any further delay.

 (iii) If a supplier to Impinj has inadequate capacity to timely fulfill both Alien’s Orders for Products and
Impinj’s other requirements for Impinj Products (including Impinj’s own use of Products), then, without limiting any of Alien’s other rights and remedies, Impinj will allocate the available capacity in a manner that proportionally
reflects Alien’s orders for Products during the previous ninety (90) days. For example, if during the previous ninety days, Alien accounted for sixty percent (60%) of the total production of Impinj Products, then in the event of
inadequate supplier capacity, Impinj will allocate sixty percent (60%) of the available capacity to meet Alien’s requirements for Products. Impinj will work with Alien in good faith to resolve any customer difficulties that may arise
during a period of inadequate capacity, and the parties may mutually agree upon an allocation formula that differs from that set forth above in order to meet urgent Alien requirements. 
 (iv) Impinj will obtain the written consent of Alien prior to implementing any changes to the form, fit, or function of the Products,
which consent may be withheld by Alien in its sole discretion. If Alien elects to withhold such consent, Impinj may implement such changes, but will continue to make available the unchanged variants of the Products to Alien. 
 (c) Acceptance of Shipments. Alien shall give notice to Impinj (and the carrier where appropriate) of discrepancies between Product ordered and
delivered, and of damage to the Product within eleven (11) business days of delivery to the Delivery Point. Lacking such notice, Alien shall be deemed to have received the Product as invoiced, provided however that receipt shall not mean
Acceptance. Alien shall accept (“Acceptance” or “Accepted”) or reject Products included in each shipment within sixty (60) days from delivery. If Alien fails to notify Impinj in writing of its rejection and the reasons
thereof within such time period, Alien will be deemed to have Accepted such shipment. Product may be returned to Impinj only after prior notification and subsequent authorization upon receipt of a return material authorization number issued by
Impinj, provided however that the Acceptance period shall be extended on a day by day basis to the extent Impinj fails to timely provide return authorization. No credit allowances for defective Product will be made or replacements therefore shipped
until Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting, assembly process, post-processing of any Product after delivery (including without limitation
Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper testing that was not authorized or directed by Impinj. Acceptance of Product shall not modify or
otherwise change the applicable Product warranties, and Acceptance shall not constitute a waiver of such Product warranties. 
  

 14 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	9.	Limited Product Warranty. 

 (a) Limited Product
Warranty. Following release of Products into production, Impinj warrants as follows: 
 (i) that such Products supplied to Alien hereunder
shall materially conform to the applicable Specifications of such Product and shall be free from defects in materials and workmanship, (the “Limited Product Warranty”) during the Limited Warranty Period. For purposes of
clarification, the foregoing Limited Product Warranty shall not be applied to any Risk Wafers, engineering wafers or any Products labeled as beta or evaluation versions; 
 (ii) that Products will be new, and free and clear of all liens, encumbrances, security interests, and other claims; 
 (iii) that to Impinj’s knowledge, the Products will not infringe or misappropriate any Intellectual Property Rights of any third party; and 
 (iv) that Impinj has the right and power to enter into this Agreement and grant to Alien the rights set forth herein. 
 (b) Alien’s sole remedy in relation to the warranties under Section 9(a) shall be that: Impinj shall replace, refund or credit, at Impinj’s sole discretion, Alien’s account for any such
Products which are returned by Alien during the warranty period set forth above, (provided that for the last Order under this Agreement, if such Products cannot be replaced, Impinj shall refund amounts to Alien) provided that: 
 (i) Impinj is promptly notified in writing upon discovery by Alien that such Products failed to conform to this Agreement with an explanation of any
alleged deficiencies, 
 (ii) if: 
 (x) still in Alien’s custody then Impinj may require that Alien return such Product, at Impinj’s request; or 
 (y) not
still in Alien’s custody but provided that Alien has agreed to repair, replace or provide a refund/credit to Alien’s customer, then Alien shall have no obligation to return Product outside its custody, and 
 (iii) Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting,
assembly process, post-processing of any Product after delivery (including without limitation Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper
testing, that was not otherwise approved or directed by Impinj. Impinj shall be responsible for all costs associated with shipping replacement Products to Alien (Duty Delivery Paid) Alien’s designated location. 
  

 15 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) DISCLAIMER. THE LIMITED WARRANTIES SET FORTH IN THIS SECTION 9 ARE IN LIEU OF
ALL CONDITIONS OR WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED CONDITION OR WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND OF ANY OTHER WARRANTY OBLIGATION ON THE PART OF IMPINJ.

  

	10.	Restrictions; Intellectual Property Rights. 

 (a)
Restrictions. Alien agrees not to: (i) sell or otherwise distribute to any third party any Product in wafer, die (except as packaged in a strap, inlay, tag, label or similar) or raw silicon form; (ii) use any Monza or Monza-2 die
that is not marked as KGD (and Alien agrees to destroy all such non-KGD die); (iii) reverse engineer or otherwise attempt to gain access to logic, structure or design of any Product; (iv) modify or create derivative works of any Product
(except as part of Alien’s FSA process); (v) use any Product in any products or systems for which errors, bugs or malfunctions could cause personal injury or death, property or environmental damage, including without limitation, medical
life support systems (which for the purposes of this Agreement shall exclude pharmaceutical or hospital patient tracking applications), on-line control of aircraft, air traffic, air navigation or aircraft communications or in the design or operation
of any nuclear facility; or (vi) cause or grant permission to any third party to do any of the foregoing. 
 (b) Monza and
Monza-2. Impinj owns and shall retain all Intellectual Property Rights in and to Monza and Monza-2. Improvements, modifications or enhancements to Intellectual Property shall be as set forth in the Intellectual Property Agreement between the
parties, dated May 5, 2005. 
 (c) Third party Infringement. Impinj shall notify Alien in the event Impinj receives or becomes
aware of any notice of any claim, suit or proceeding alleging that Monza infringes any third party Intellectual Property Rights. Alien shall notify Impinj in the event Alien receives or becomes aware of any notice of any claim, suit or proceeding
alleging that FSA Intellectual Property or Alien’s technology used to assemble Monza chips infringes any third party Intellectual Property Rights. 
 (d) Monza-FSA. Ownership of and licenses to Intellectual Property and Intellectual Property Rights shall be as set forth in the Intellectual Property Agreement between the parties, dated May 5, 2005.

 (e) Reservation of Rights. Each party reserves all rights not expressly granted in this Agreement, and no licenses are granted by
either party to the other party under this Agreement, whether by implication, estoppel or otherwise, except as expressly set forth herein. 
 (f) Covenant of Further Assurances. Each party shall, without demanding any further consideration therefor, at the request and expense of the requesting party take all such actions and execute all such documents as reasonably
requested by the other party, in order to effect the intent of this Section 10. 
  

 16 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	11.	Confidentiality; Press Releases. 

 (a) Duty to
Maintain Confidentiality. Each party agrees to accept Confidential Information from the other party solely for use in connection with performance of its obligations and exercise of its rights granted under this Agreement and that for a period of
five (5) years from the date of disclosure it will hold in strict confidence and not disclose, publish, or disseminate such Confidential Information to anyone other than those of its employees and subcontractors with a need to know and who have
executed appropriate confidentiality agreements, nor use Confidential Information for its own or any third party’s benefit, without the prior written approval of an authorized representative of the originating party. The receiving party will
protect Confidential Information of the disclosing party from disclosure, publication, dissemination and unauthorized use with the same degree of care the receiving party uses to protect its own confidential and proprietary information of similar
nature, but in no event less than a reasonable degree of care. Notwithstanding the foregoing, and subject to the restrictions in Section 2(a)(iii), in no event shall Alien be prevented from distributing information about its products that
include Products purchased hereunder provided that such information does not include Confidential Information of Impinj. 
 (b)
Exceptions. The receiving party may disclose Confidential Information if required by operation of law or any tribunal of competent jurisdiction, provided that it will take reasonable steps to first give the originating party sufficient prior
notice to contest the order to disclose, and must cooperate with the originating party in any efforts by the originating party to obtain a protective order or other confidential treatment. The parties shall have the right to disclose the terms of
this Agreement to attorneys, government agencies, financial advisors and potential investors and acquirers (of the party or the party’s relevant foundry, division, or product line), subject to reasonable confidentiality provisions which are no
less restrictive than those provided for herein. 
 (c) Injunctive Relief. The parties acknowledge that any breach or threatened
breach of the obligations of confidentiality contained in this Section 11 may cause substantial harm to the non-breaching party that may not be reasonably or adequately compensated with monetary damages. Accordingly, in addition to any
other available remedies, the parties recognize each party’s right to seek injunctive relief in connection with such breach or threatened breach. 
 (d) Press Releases. The parties agree to issue two (2) joint press releases upon the completion of the milestones as follows: (1) one press release announcing the sampling of Alien-assembled straps or
inlays incorporating Monza die (as set forth in Section 2(a)(iii)) upon the commencement of such sampling; and (2) one press release announcing the commencement of volume production of Monza upon Alien’s order of the first
production quantities of Monza. Each such press release shall indicate that the silicon is produced by Impinj and the straps and inlays are produced by Alien. 
  

	12.	Indemnification. 

 (a) By Impinj. Impinj
shall indemnify, defend and hold harmless Alien from and against any and all third party claims, actions, losses, liabilities, damages, costs and expenses (including but 

  

 17 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
not limited to reasonable attorneys’ fees and costs) to the extent based on a claim that any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA,
only to the extent that Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights) supplied by Impinj to Alien hereunder constitutes infringement or misappropriation of any third party Intellectual Property
Rights and Alien compliance with Impinj’s specifications. (collectively a “Product IP Claim”). Impinj shall not be obligated to defend or be liable for costs and damages if: (i) the infringement arises out of compliance
with Alien’s specifications or instructions or the FSA Intellectual Property; (ii) the infringement arises from a combination with, an addition to, or a modification of the Products after delivery by Impinj; or (iii) the infringement
arises from use of the Products, or any part thereof, in the practice of a process. Impinj’s obligations hereunder shall not apply to any infringement occurring after (i) Impinj has received notice of such suit or proceeding or other
communication alleging the infringement and (ii) Impinj provides such notice to Alien, unless Impinj gives written permission for such continuing infringement. In the event Impinj provides Alien with such notice, and the infringement does not
arise under conditions described in Section 12(b), Alien shall have the right to terminate this Agreement and any Orders without cost or penalty. 
 If
any infringement by Impinj is alleged prior to completion of delivery of the Products under this Agreement, Impinj may decline to make further shipments without being in breach of this Agreement. 
 Without limiting Impinj’s obligations above, if any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA, only to the extent that Monza or Monza-2, as
applicable, alone would have infringed the same Intellectual Property Rights without the FSA Intellectual Property) supplied by Impinj to Alien hereunder shall be held to directly infringe Intellectual Property Rights, and Alien shall be enjoined
from using the same, Impinj shall (or if Impinj reasonably believes that such an injunction may be issued, Impinj may) use reasonable efforts, at its option and at its expense, (i) to procure for Alien the right to use such products free of any
liability for infringement, or (ii) to replace such products with a noninfringing substitute otherwise complying substantially with all requirements of this Agreement, or if the aforesaid enjoinment is confirmed and neither of the actions under
(i) or (ii) above are available on commercially reasonable terms, to (iii) accept return of such products and refund the purchase price of such returned products. 
 (b) By Alien. Alien shall indemnify, defend and hold harmless Impinj from and against any and all claims, actions, losses, liabilities, damages,
costs and expenses (including but not limited to reasonable attorneys’ fees and costs, but excluding any Product IP Claim) to the extent based on a claim that (i) any strap or inlay product from Alien incorporating any Product (but not if
Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights without the strap or inlay product from Alien); (ii) Impinj’s compliance with Alien’s specifications; (iii) any combination with,
addition to, or modification of the Products after delivery by Impinj to Alien; or (iv) the FSA Intellectual Property; infringes or misappropriates any third party Intellectual Property Rights. 
 (c) Procedures. All indemnification obligations under this section shall be subject to the following requirements: (i) the indemnified party
shall provide the indemnifying party with 

  

 18 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
prompt written notice of any claim; (ii) the indemnified party shall permit the indemnifying party to assume and solely control the defense or
settlement of any claim (provided, that neither party shall enter into any settlement providing for any restriction on the other party without the other party’s prior written consent, such consent not to be unreasonably withheld);
(iii) the indemnified party shall provide proper and full information and all reasonable assistance to defend or settle any such claim, at the indemnifying party’s request and expense; and (iv) the indemnified party shall not have
compromised or settled any such claim without the indemnifying party’s prior written consent. In addition, the indemnifying party shall not be responsible for any costs, expenses, compromises, or settlements incurred or made by the indemnified
party without the indemnifying party’s prior written consent, and the indemnified party may, at its own expense, participate in its defense of any claim. 
 (d) Sole Remedy. THE FOREGOING PROVISIONS OF THIS SECTION 12 STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF EACH PARTY AND THE EXCLUSIVE REMEDY OF THE OTHER PARTY, WITH RESPECT TO ANY ALLEGED OR
ACTUAL INFRINGEMENT OF PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS OR OTHER INTELLECTUAL PROPERTY RIGHTS BY THE PRODUCTS. 
  

	13.	Term and Termination. 

 (a) Term. The term of
this Agreement shall commence on the Effective Date and expire six (6) months after the delivery of the fifty millionth Product (excluding Risk Wafers delivered pursuant to Sections 3(b) and 3(c)), unless earlier terminated as
provided herein. 
 (b) Termination. 
 (i) Delay of Product Acceptance. In the event that the Product Acceptance Date does not occur by December 31, 2005, this Agreement shall automatically terminate upon such date unless prior to such date the
parties agree (via written notice sent to the individuals specified in Section 15(g)) to extend the date by which the Product Acceptance must occur. If the parties so agree and the Product Acceptance does not occur by such extended date,
this Agreement shall automatically terminate on such extended date unless the parties otherwise agree to subsequently re-extend the date by which the Product Acceptance must occur. If this Agreement is terminated pursuant to this
Section 13(b)(i), Alien shall have no obligation to pay Impinj the Pre-Paid Amount or purchase the Minimum Purchase Amount. 
 (ii) For Cause. Either party may terminate this Agreement upon written notice in the event the other party materially breaches this Agreement and fails to cure such breach within thirty (30) days after the
date of written notice thereof by such party. 
 (iii) For Insolvency. Either party may terminate this Agreement by
written notice in the event: (1) the other party voluntarily enters into proceedings in bankruptcy or insolvency; (2) the other party makes an assignment for the benefit of creditors; (3) a petition is filed against the other party
under a bankruptcy law, a corporate reorganization law, or any other law for relief of debtors or similar law analogous in purpose or effect, which petition is not dismissed within one hundred and twenty (120) days of filing thereof; or
(4) the other party 

  

 19 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
enters into liquidation or dissolution proceedings or a receiver is appointed with respect to any assets of the other party, which appointment is not vacated
within one hundred and twenty (120) days. 
 (c) Effect of Termination. The following provisions shall survive any termination or
expiration of this Agreement: Sections 1, 4 (except for termination by Alien pursuant to Section 13(b)(i)), 5 (except for termination by Alien pursuant to Section 13(b)(i)), 9, 10,
11, 12, 13(c), 14 and 15. Nothing contained herein shall limit any other remedies that either party may have for the default of the other party under this Agreement nor relieve either party of any of its
obligations incurred prior to any expiration or termination of this Agreement. 
 (d) No Liability for Termination. Neither party
shall incur any liability or compensation obligation whatsoever for any damage (including and without limitation damage to or loss of goodwill or investment), loss or expenses of any kind suffered or incurred by the other party arising from or
relating to any termination of this Agreement pursuant to the terms hereof, whether or not such party is aware of any such loss or expenses. Termination is not the sole remedy and except as otherwise provided herein, all other remedies remain
available to each party. 
  

	14.	Limitation of Liability. 

 (a) EXCEPT FOR ANY BREACH
OF OR LIABILITY ARISING UNDER SECTIONS 10, OR 11, NEITHER PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHETHER SUCH DAMAGES ARE ALLEGED AS A RESULT OF TORTIOUS CONDUCT OR BREACH OF CONTRACT OR OTHERWISE, EVEN
IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. SUCH EXCLUDED DAMAGES SHALL INCLUDE BUT SHALL NOT BE LIMITED TO COST OF REMOVAL AND REINSTALLATION OF GOODS, LOSS OF GOODWILL, LOSS OF PROFITS, LOSS OF USE OF DATA, INTERRUPTION OF
BUSINESS OR OTHER ECONOMIC LOSS. REMEDIES PROVIDED HEREIN ARE INTENDED TO BE EXCLUSIVE (IN LIEU OF ANY OTHER REMEDY WHICH WOULD OTHERWISE HAVE BEEN AVAILABLE TO THE PARTIES AT LAW OR IN EQUITY). 
 (b) EXCEPT FOR ANY BREACH OF OR LIABILITY ARISING UNDER SECTIONS 4, 5(a), 10 OR 11, NEITHER PARTY’S TOTAL LIABILITY ARISING OUT OF OR
UNDER THIS AGREEMENT OR FOR BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED ONE AND ONE QUARTER (1.25x) THE TOTAL AMOUNTS PAID OR PAYABLE TO
IMPINJ HEREUNDER. 
 (c) EACH PARTY’S TOTAL LIABILITY ARISING OUT OF OR UNDER SECTION 4 OR FOR BREACH OF
SECTION 4, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED THREE MILLION EIGHT HUNDRED THOUSAND DOLLARS ($3,800,000) . EACH PARTY’S TOTAL LIABILITY
ARISING OUT OF OR UNDER SECTION 5(a) OR FOR BREACH OF SECTION 5(a), WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION 

  

 20 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED FIVE HUNDRED THOUSAND DOLLARS ($500,000). 
  

	15.	General. 

 (a) Governing Law; Venue. This
Agreement shall be governed by and construed under the laws of the State of California without regard to conflict of laws principles. The parties consent to the exclusive jurisdiction of, and venue in either Orange County, California, or Santa Clara
County, California, for any dispute arising out of or related to this Agreement. 
 (b) Assignment. Neither party shall transfer,
assign or delegate this Agreement or any rights or obligations hereunder, in whole or in part, whether voluntarily, by operation of law or otherwise, without the prior written consent of the other party, which consent shall not be unreasonably
withheld. Any purported transfer, assignment or delegation without such prior written consent will be null and void and of no force or effect. Notwithstanding the foregoing, each party shall have the right to assign this Agreement to any successor
to substantially all its business or assets to which this Agreement relates, whether by merger, sale of assets, sale of stock, reorganization or otherwise. Subject to the foregoing, this Agreement inures to the benefit of permitted successors and
assigns of each party. 
 (c) Waivers; Modification. No failure or delay (in whole or in part) by either party in exercising any
right, power, or remedy under this Agreement shall operate as a waiver of any such right, power, or remedy. No waiver or modification of any provision of this Agreement shall be effective unless in writing and signed by both parties. Any waiver by
either party of any provision of this Agreement shall not be construed as a waiver of any other provision or of such provision on any other occasion. 
 (d) Entire Agreement. Exhibits A and B are incorporated herein by this reference. This Agreement (including the Exhibits hereto) constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter hereof and supersedes any and all other agreements, written or oral, that the parties heretofore may have had with respect to the subject matter herein, including without limitation the term sheet signed by the
parties on May 20, 2005. 
 (e) Export. Each party agrees to fully comply with all applicable United States and foreign laws and
regulations with respect to the export, re-export, diversion or transfer of any products, technology, and information related to or exchanged under this Agreement, including without limitation the Export Administration Regulations issued by the
Department of Commerce, the International Trade Administration, and the Bureau of Export Administration, and the International Traffic in Arms Regulations (ITAR), including without limitation obtaining any necessary consents and requesting or filing
any documents. 
 (f) Severability. In the event any provision of this Agreement (or portion thereof, including the Exhibits hereto)
is determined by a court of competent jurisdiction to be invalid, illegal, or otherwise unenforceable, such provision shall be deemed to have been deleted from 

  

 21 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
this Agreement, while the remainder of this Agreement shall remain in full force and effect according to its terms. 
 (g) Notices. All notices permitted or required under this Agreement shall be in writing and shall be delivered in person, or by overnight delivery
service or by first class, registered or certified mail, postage prepaid, to the address of the party specified below or such other address as either party may specify in writing. Such notice shall be deemed to have been given upon delivery.

  

			
	 If to Impinj:
	  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Vinay Gokhale

	
	 With a required copy to:

		
		  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Legal Department

		
	 If to Alien:
	  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Thomas M.
Pounds

	
	With a required copy to:
		
		  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Legal
Department

 (h) Independent Contractors. The parties are independent contractors, and nothing in this
Agreement is intended to create any agency, partnership or joint venture relationship between them. 
 (i) Headings. The section
headings contained in this Agreement are included for convenience only, and shall not limit or otherwise affect the terms of this Agreement. 
 (j) Counterparts. This Agreement may be executed in any number of counterparts, and each executed counterpart shall have the same force and effect as an original instrument. 
 (k) Force Majeure. Neither party shall be responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its
reasonable control (other than payment of money), including but not limited to Acts of God, government actions, war, civil 

  

 22 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
disturbance, insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by suppliers or subcontractors, transportation difficulties,
shortage of energy, raw materials or equipment, or the other party’s fault or negligence. In the event of any such delay the date of delivery shall, at the request of such party, be deferred for a period equal to the time lost by reason of the
delay. 
 [Signature Page Follows] 
  

 23 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
Effective Date. 
  

									
	 Impinj:
	 		 	 Alien:

			
	 Impinj, Inc.
	 		 	 Alien Technology Corporation

					
	 By:
	 	 /s/ William T. Colleran
	 		 	 By:
	 	 /s/ John Payne

					
	 Name:
	 	 William T. Colleran
	 		 	 Name:
	 	 John Payne

					
	 Title:
	 	 President
	 		 	 Title:
	 	 Chief Operating Officer

  

 24 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit A 
 Monza Specifications 
 [***] 
  

 25 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing Procedures 
  

 26 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing 
 This exhibit describes the test procedures currently employed by Impinj on Monza Products. This test
procedure can be modified with the mutual agreement of the parties. The Impinj patented Monza test procedure uses dedicated hardware and software to test each wafer with minimal test time and maximal coverage relative to a conventional approach. The
test procedure requires dedicated circuits placed in the scribe lanes (area that is consumed when die sawing is performed) that enable a bypass port that gives parallel access to all die in the reticle; this port is referred to as the Reticle Test
Interface (“RTI”), and consists of a die site with [***]. This circuit interfaces with an array of Die Test Interfaces (“DTI”), one for each chip in the reticle and adjacent to the chip it tests. A bus structure with redundant
elements for fault tolerance connects the single RTI with the many DTIs. 
 In a conventional wafer probe test, each die is independent and is tested via its
primary I/O ports. If applied to RFID projects, with tens of thousands of die per wafer, conventional wafer probe tests effectively have a single serial interface that operates at UHF frequencies. This leads to poor test coverage, very long test
times, and unforgiving hardware fixtures. 
 In contrast, the Impinj approach provides full wafer-probe testing at that is very cost effective, and at a high
level of coverage. Monza wafers have nearly [***] yieldable die sites (gross die per wafer, or GDPW), and after DTI testing, typically [***] are identified as good die (net die per wafer, or NDPW). This shows a raw yield of about [***], which is
slightly higher than the prediction of the fab yield model at [***], consistent with a robust design. DTI testing does not enable 100% fault detection, however, and our models for DPPM reduction predict a residual test escape rate of [***], or
[***]. Hence, outgoing quality levels rise to [***], and become the practical meaning of “known good die”. 
 For reference, a series of [***]
tests comprising digital functionality over the Gen2 command set, key analog parameters, and read+write pattern testing of the NVM, is performed on the wafer. All circuit blocks are tested with the exception of the rectifiers and parts of the modem,
since their operation depends on a microwave signal. This constitutes the majority of the residual [***] loss. This remaining factor can be dealt with by a minimal, and very fast, RF test after inlay assembly, which is needed in any event to
identify assembly losses. Note that the net yield of inlays or straps rises from an estimated [***] to [***] (for an assumed [***] assembly yield), or a factor of [***] reduction in scrap rates, as a result of this capability. 
  

 27 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]